Neisvac-C

N. meningitidis group C (strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid, the active ingredient in Neisvac-C, is a vaccine presented as an injectable solution for intramuscular use. It is used to prevent invasive disease caused by Neisseria meningitidis serogroup C in individuals at risk, such as adolescents, travelers and outbreak settings.

GNH USA supplies Neisvac-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neisvac-C is a conjugate vaccine that targets the meningococcal disease pathway caused by serogroup C bacteria. - Meningococcal meningitis (serogroup C): reduces the risk of meningitis caused by Neisseria meningitidis group C. - Meningococcal septicemia (serogroup C): lowers the incidence of bloodstream infection due to serogroup C. - Meningococcal carriage (serogroup C): helps decrease nasopharyngeal carriage and transmission of the organism.

Neisvac-C may cause local and systemic reactions after injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature rise. - Headache or fatigue: mild systemic symptoms.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder. - Severe hypotension or shock: may occur shortly after dosing. - Seizures: uncommon neurologic event. - Persistent high fever: prolonged temperature elevation.

Before administering Neisvac-C, consider the following safety measures. - Allergy assessment: avoid use in individuals with known hypersensitivity to any vaccine component. - Pregnancy: administer only if the expected benefit outweighs potential risk, as data are limited. - Immunocompromised patients: vaccine may be less effective; monitor immune response. - Concomitant vaccines: can be given at separate sites, but observe for additive local reactions. - Age restrictions: not recommended for children under the age specified in the product label. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other agents that modify immune response.

Major Interactions (Avoid): - Severe allergic reaction to a previous dose: contraindicates further administration. - Immunoglobulin or blood products given within 4 weeks: may markedly reduce vaccine‑induced immunity.

Moderate Interactions (Monitor Closely): - Concurrent administration of other vaccines: monitor for increased local or systemic reactions. - Prophylactic antipyretics (e.g., acetaminophen): may blunt antibody response. - Ongoing immunosuppressive therapy: may lower vaccine efficacy, requiring serologic assessment.